Skip to main content
. Author manuscript; available in PMC: 2015 Mar 5.
Published in final edited form as: J Alzheimers Dis. 2012;28(4):783–794. doi: 10.3233/JAD-2011-111208

Fig. 5.

Fig. 5

Co-labeling studies between pE(3)Aβ and thioflavine-S in AD at various Braak stages. Co-labeling studies between pE(3)Aβ and thioflavine-S was conducted samples from the frontal cortex in patients with Braak stages of I to VI. a, c, e) D129 immunoreactivity in the frontal cortex of early AD patients with Braak stages I, II, and III respectively. b, d, f) Thioflavine-S staining in the frontal cortex of early AD patients with Braak stages I, II, and III respectively. g, i, k) D129 immunoreactivity in the frontal cortex of advanced AD patients with Braak stage IV, V, and VI respectively, grey dots delineate perimeter of the plaque. h, j, l) Thioflavine-S staining in the frontal cortex of advanced AD patients with Braak stages IV, V, and VI respectively, grey dots delineate perimeter of the plaque. Scale bar = 30 µM.